UC Berkeley researchers report experimental compound increased energy expenditure by up to 18% in mice
UC Berkeley researchers reported in Science Advances that TOFA increased energy expenditure by up to 18% in mice and helped obese mice lose fat while preserving lean muscle. The compound also improved insulin sensitivity, lowered triglycerides, and enhanced GLP-1 medication effects in the animal study. It matters because it explores increasing energy expenditure as a complement to appetite-suppressing obesity drugs, though human safety and efficacy are not established.
UC Berkeley researchers reported in Science Advances that the experimental compound 5-tetradecyloxy-2-furoic acid, or TOFA, increased energy expenditure by up to 18% in mice without making them more active or raising body temperature. The study tested a weight-loss strategy aimed at spending more calories rather than reducing food intake, the main route used by GLP-1 drugs such as Ozempic and Wegovy. The release did not specify the number of mice studied.
In obese mice, TOFA improved insulin sensitivity, lowered triglycerides, and improved features of fatty liver disease. Weight loss occurred mainly as fat loss, while lean muscle mass was not significantly reduced, according to the source. The compound also enhanced the effects of GLP-1 medications when combined, but the release did not give detailed human-relevant dosing, duration, or safety data. The evidence comes from animal experiments published in Science Advances.
The finding matters because GLP-1 drugs have changed obesity care but can cause nausea, poor nutrition, and muscle loss when appetite drops sharply. TOFA targets a different lever: increasing energy use and activating genes that take up and burn fat while interfering with lipid production. The source describes that dual mechanism as a route distinct from appetite suppression. Still, mouse metabolism differs from human metabolism, and compounds that raise energy use can also stress the body or trigger unintended effects.
The animal results addressed fat loss, muscle preservation, blood sugar, and blood fats, all relevant to obesity, diabetes, and fatty liver disease. Muscle supports mobility, strength, and long-term metabolic health, so preserving it during weight loss is a key clinical goal. The study points to a possible route toward drugs that complement GLP-1 treatments rather than replacing them. The source states that effectiveness and safety have not yet been established in humans.
People with obesity, diabetes, or fatty liver disease are most directly affected, because the animal results addressed fat loss, muscle preservation, blood sugar, and blood fats. The result matters because it explores increasing energy expenditure as a complement to appetite-suppressing obesity drugs.
Sources (1)
- [1]Original source(https://www.sciencedaily.com/releases/2026/11/261118073918.htm)